Rese-cel Holds Immunomodulator-Free Responses at One Year Across Three Autoimmune Diseases
CABA is trading near its 52-week low of $1.18 (14% above the low).
Summary
Cabaletta presented new Phase 1/2 rese-cel data at ACR Convergence 2026 showing durable, immunomodulator-free responses across dermatomyositis, lupus nephritis and systemic sclerosis. All 6 of 6 dermatomyositis patients held moderate-to-major TIS responses through one year, with 5 of 6 reaching that level by Week 16 — the timepoint that maps to the primary endpoint of the ongoing registrational DM/ASyS cohort. All 5 biopsied lupus nephritis patients achieved DORIS remission off immunomodulators with histologic response or remission, and 5 of 7 systemic sclerosis patients hit rCRISS-50 at one year with a 9% mean FVC improvement in the five ILD patients. Safety across 71 patients was clean: 94% had no or Grade 1 CRS, 96% had no ICANS, and no IEC-HS was reported. The data support the registrational path but do not change near-term timing — topline DM/ASyS results are guided to the second half of 2027 and the myositis BLA to the first quarter of 2028. This lands three days after the Q3 update that showed $299.4M in cash and removed the going-concern warning, so financing risk is off the table while the clinical readout remains the real driver.
At the time of this announcement, CABA was trading at $1.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $220.4M. The 52-week trading range was $1.18 to $4.23. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.